Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Jun Yu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3435-6550; OpenAlex author ID A5033829154, A5123452065, A5126411945. Sources: OpenAlex.

Their work

Papers
70 (first author 8, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
269
Papers, trials and grants by year

2012: 1 paper · 2013: 2 papers · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: 6 papers · 2018: 5 papers · 2019: 9 papers · 2020: 3 papers · 2021: 6 papers · 2022: 12 papers · 2023: 9 papers · 2024: 3 papers · 2025: 5 papers · 2026: 7 papers

Papers 50 of 70

  1. An Insulin-Exosome-TNFAIP8 Axis Drives Stromal Fibrosis and Therapeutic Resistance in Pancreatic Cancer. Co-author DOI 10.1002/advs.202515606↗
  2. Pathomics Signature for Prognosis and CA19-9 Interception in Pancreatic Ductal Adenocarcinoma: A Real-Life, Multi-Center Study. Co-author DOI 10.1002/advs.202515952↗
  3. Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancreatic cancer. Co-author DOI 10.1038/s41392-026-02641-4↗
  4. Sitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 tri… Co-author DOI 10.1038/s41392-026-02966-0↗
  5. Rationally and in silico guided APOBEC3F-directed CBE for enhanced PDAC genetic therapy. Co-author DOI 10.1038/s42003-026-09770-0↗
  6. Development and Prospective Validation of a Cell-free DNA-Based Model for the Early Detection of Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-25-0323↗
  7. Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic-Epigenetic Rewiring. Co-author DOI 10.1158/2159-8290.cd-25-1627↗
  8. The Evolutionary Trajectory and Prognostic Value of GITR+ Tregs Reprogramed by Tumor-Intrinsic PD-1/c-MET Signaling in Pancreatic Cancer. Co-author DOI 10.1002/advs.202500806↗
  9. The nuclear condensates of ESE3/EHF induce cellular senescence without the associated inflammatory secretory phenotype in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2024.217408↗
  10. Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pancreatic cancer. Co-author DOI 10.1038/s41467-025-67197-3↗
  11. Intratumoral IL-33 + CD4 + FoxP3 + regulatory T cell infiltration determines poor clinical outcomes and intensive immunoevasive contexture in patients with pan… Co-author DOI 10.1097/js9.0000000000002733↗
  12. Integrated pretreatment stratification system for pancreatic cancer: combining anatomical resectability and tumor biological parameters. Co-author DOI 10.20892/j.issn.2095-3941.2025.0213↗
  13. Clinical and pathological factors associated with survival in patients with pancreatic cancer who receive adjuvant therapy after neoadjuvant therapy: A retrosp… Co-author DOI 10.1016/j.surg.2024.01.008↗
  14. CD64+ fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-l… Co-author DOI 10.1136/gutjnl-2024-332371↗
  15. Transfer Learning Reveals Cancer-Associated Fibroblasts Are Associated with Epithelial-Mesenchymal Transition and Inflammation in Cancer Cells in Pancreatic Du… Co-author DOI 10.1158/0008-5472.can-23-1660↗
  16. More Explorations Needed to Assess Matrix Metalloproteinase 7 Expression When Predicting the Pathologic Response to Neoadjuvant Therapy for Pancreatic Ductal A… First author DOI 10.1001/jamasurg.2022.4976↗
  17. Tumor Microenvironment Responsive CD8+ T Cells and Myeloid-Derived Suppressor Cells to Trigger CD73 Inhibitor AB680-Based Synergistic Therapy for Pancreatic Ca… Co-author DOI 10.1002/advs.202302498↗
  18. Oncologic resection of pancreatic cancer with isolated liver metastasis: Favorable outcomes in select patients. Co-author DOI 10.1002/jhbp.1303↗
  19. Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study. First author DOI 10.1002/mco2.216↗
  20. Engineered TCR T-cell therapy targeting mass spectrometry-identified natural epitope in PDAC. Co-author DOI 10.1016/j.canlet.2023.216366↗
  21. Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer. Last author DOI 10.1097/js9.0000000000000200↗
  22. Surgical Decision-Making in Pancreatic Ductal Adenocarcinoma: Modeling Prognosis Following Pancreatectomy in the Era of Induction and Neoadjuvant Chemotherapy. Co-author DOI 10.1097/sla.0000000000004915↗
  23. Normalization of tumor markers and a clear resection margin affect progression-free survival of patients with unresectable pancreatic cancer who have undergone… Co-author DOI 10.1186/s12885-023-10529-7↗
  24. DNA damage repair mutations in pancreatic cancer- prognostic or predictive? Co-author DOI 10.3389/fonc.2023.1267577↗
  25. Prevalence of Germline Sequence Variations Among Patients With Pancreatic Cancer in China. Co-author DOI 10.1001/jamanetworkopen.2021.48721↗
  26. Association of Matrix Metalloproteinase 7 Expression With Pathologic Response After Neoadjuvant Treatment in Patients With Resected Pancreatic Ductal Adenocarc… Last author DOI 10.1001/jamasurg.2022.1362↗
  27. Germline Variants in DNA Damage Repair Genes: An Emerging Role in the Era of Precision Medicine in Pancreatic Adenocarcinoma. Last author DOI 10.1002/ags3.12514↗
  28. New criteria of resectability for pancreatic cancer: A position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS). Co-author DOI 10.1002/jhbp.1049↗
  29. Tumor-associated N1 and N2 neutrophils predict prognosis in patients with resected pancreatic ductal adenocarcinoma: A preliminary study. Co-author DOI 10.1002/mco2.183↗
  30. Obstructive sleep apnea predicts pathologic response to neoadjuvant therapy in resected pancreatic ductal adenocarcinoma. Last author DOI 10.1002/mco2.184↗
  31. Deep insight into lymph node metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2022.06.027↗
  32. Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy. Co-author DOI 10.1016/j.surg.2021.10.015↗
  33. Inflammatory Signaling in Pancreatic Cancer Transfers Between a Single-cell RNA Sequencing Atlas and Co-Culture Co-author DOI 10.1101/2022.07.14.500096↗
  34. RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1200/po.21.00404↗
  35. Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an In… Last author DOI 10.1245/s10434-021-11081-z↗
  36. Catenin delta 1 mediates epithelial–mesenchymal transition, proliferation, migration, and invasion of pancreatic cancer via the Wnt/β-catenin pathway Co-author DOI 10.21203/rs.3.rs-1976828/v1↗
  37. Ovarian Metastasis from Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s00268-021-06209-x↗
  38. Reliable Detection of Somatic Mutations for Pancreatic Cancer in Endoscopic Ultrasonography-Guided Fine Needle Aspirates with Next-Generation Sequencing: Impli… Co-author DOI 10.1007/s11605-021-05078-y↗
  39. Lymph Node Metastatic Patterns and Survival Predictors Based on Tumor Size in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s12325-021-01819-2↗
  40. Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017. Co-author DOI 10.1016/j.canlet.2020.10.039↗
  41. Recurrence in Patients Achieving Pathological Complete Response After Neoadjuvant Treatment for Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003570↗
  42. Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis. Last author DOI 10.1158/1078-0432.ccr-20-1746↗
  43. Association of Germline Variants in Human DNA Damage Repair Genes and Response to Adjuvant Chemotherapy in Resected Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1016/j.jamcollsurg.2020.06.019↗
  44. Detection of Circulating Tumor DNA in Patients with Pancreatic Cancer Using Digital Next-Generation Sequencing. First author DOI 10.1016/j.jmoldx.2020.02.010↗
  45. Radiofrequency ablation in combination with an mTOR inhibitor restrains pancreatic cancer growth induced by intrinsic HSP70. Co-author DOI 10.1177/1758835920953728↗
  46. Single-cell sequencing defines genetic heterogeneity in pancreatic cancer precursor lesions. Co-author DOI 10.1002/path.5194↗
  47. Cell-intrinsic PD-1 promotes proliferation in pancreatic cancer by targeting CYR61/CTGF via the hippo pathway. Co-author DOI 10.1016/j.canlet.2019.06.013↗
  48. Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer. Co-author DOI 10.1016/j.ejso.2019.04.007↗
  49. The importance of circulating and disseminated tumor cells in pancreatic cancer. Co-author DOI 10.1016/j.sopen.2019.08.002↗
  50. Pancreatic cancer arising in the remnant pancreas is not always a relapse of the preceding primary. Co-author DOI 10.1038/s41379-018-0183-7↗

Closest collaborators

The 25 strongest of 269 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jin Peng He · 28 shared papers, 2017–2024 · strength 2.82
  2. Ning Pu · 16 shared papers, 2019–2026 · strength 2.33
  3. Christopher Lee Wolfgang · 25 shared papers, 2013–2024 · strength 2.20
  4. Richard Andrew Burkhart · 19 shared papers, 2018–2024 · strength 2.03
  5. Jihui Hao · 9 shared papers, 2024–2026 · strength 1.86
  6. Sami Shoucair · 9 shared papers, 2021–2023 · strength 1.60
  7. Ammar A. Javed · 13 shared papers, 2018–2023 · strength 1.41
  8. Hanlin Yin · 9 shared papers, 2019–2026 · strength 1.41
  9. William R. Burns · 11 shared papers, 2020–2024 · strength 1.40
  10. Xiuchao Wang · 7 shared papers, 2024–2026 · strength 1.39
  11. Tiansuo Zhao · 7 shared papers, 2024–2026 · strength 1.39
  12. Ralph H. Hruban MD · 18 shared papers, 2012–2023 · strength 1.26
  13. Matthew John Weiss · 15 shared papers, 2017–2023 · strength 1.21
  14. Joseph R. Habib · 9 shared papers, 2019–2023 · strength 1.15
  15. Yongjie Xie · 6 shared papers, 2024–2026 · strength 1.15
  16. Christopher L. Wolfgang · 9 shared papers, 2021–2024 · strength 1.15
  17. Qiangda Chen · 7 shared papers, 2020–2026 · strength 1.14
  18. Wenchuan Wu · 7 shared papers, 2019–2025 · strength 1.10
  19. Benedict Kinny‐Köster · 8 shared papers, 2021–2024 · strength 1.04
  20. Yukuan Feng · 5 shared papers, 2025–2026 · strength 1.03
  21. Michael Goggins · 16 shared papers, 2012–2020 · strength 1.01
  22. Tianxing Zhou · 5 shared papers, 2024–2026 · strength 1.00
  23. Lei Zheng · 9 shared papers, 2019–2024 · strength 0.99
  24. Wenhui Lou · 6 shared papers, 2019–2026 · strength 0.99
  25. Yiping Zou · 5 shared papers, 2024–2026 · strength 0.97

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.